Actively Recruiting
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2026-01-20
550
Participants Needed
1
Research Sites
310 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs overall survival (OS) for participants with tumors that show positive programmed cell death ligand 1 (PD-L1) expression.
CONDITIONS
Official Title
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis confirmed by tissue or cytology as gastric or gastroesophageal junction adenocarcinoma
- Metastatic or locally advanced disease that cannot be removed by surgery
- Disease progressed after first-line therapy containing platinum/fluoropyrimidine or platinum/taxane
- Willingness to provide tumor tissue for PD-L1 testing
- Known HER-2/neu status; if positive, prior trastuzumab treatment documented
- ECOG performance status 0 to 1
- Life expectancy greater than 12 weeks
- Signed informed consent forms
- Adequate bone marrow, liver, and kidney function
You will not qualify if you...
- Squamous cell or undifferentiated gastric cancer
- Active central nervous system metastases or carcinomatous meningitis
- Active or suspected autoimmune disease, except stable type I diabetes on insulin, hypothyroidism on hormone therapy, or controlled skin diseases without recent worsening
- Significant cardiovascular or cerebrovascular diseases
- Uncontrolled high blood pressure
- Digestive tract bleeding history within 3 months or bleeding tendency
- Arterial or venous thrombosis events within 6 months before randomization
- Previous treatment with anti-PD-1/PD-L1, anti-CTLA-4 antibodies, or VEGFR inhibitors
- Chemotherapy, radiotherapy, or surgery within 4 weeks before study drug administration
- Unresolved adverse events greater than CTCAE Grade 1
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Affiliated Hospital, Academy of Military Medical Sciences
Beijing, China
Actively Recruiting
Research Team
Q
Quanren Wang, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here